SI
EBS icon

Stirlingshire Investments’s Emergent Biosolutions EBS Stock Holding History

Stirlingshire Investments’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Sell
17,702
-1,583
-8% -$13.2K 0.11% 218
2026
Q1 		$160K Sell
19,285
-1,825
-9% -$18.9K 0.14% 194
2025
Q4 		$261K Buy
+21,110
New +$226K 0.23% 138

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Stirlingshire Investments's EBS Position: Q2 2026 in Review

Stirlingshire Investments reduced its Emergent Biosolutions (EBS) stake by 8.2% in Q2 2026, selling an estimated $13.2K and leaving 17,702 shares worth $148K. The position accounts for 0.11% of the portfolio, ranked #218.

Stirlingshire Investments first reported a position in EBS in Q4 2025 and has held it in 3 quarters since. The position peaked at $261K in Q4 2025. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Stirlingshire Investments held 17,702 shares of Emergent Biosolutions worth $148K as of Q2 2026.
  • Stirlingshire Investments sold 1,583 Emergent Biosolutions shares in Q2 2026, an estimated $13.2K.
  • Emergent Biosolutions made up 0.11% of Stirlingshire Investments's portfolio in Q2 2026, its #218 holding.
  • Stirlingshire Investments first reported a position in Emergent Biosolutions in Q4 2025 and has held it in 3 quarters since.
  • Stirlingshire Investments's Emergent Biosolutions position peaked at $261K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Stirlingshire Investments's 13F filing for Q2 2026, filed 31 Jul 2026.